Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
4 studies found for:    SGN-CD19A
Show Display Options
Rank Status Study
1 Active, not recruiting A Safety Study of SGN-CD19A for B-Cell Lymphoma
Conditions: Burkitt Lymphoma;   Lymphoma, Follicular;   Lymphoma, Large B-Cell, Diffuse;   Lymphoma, Mantle-Cell;   Precursor B-cell Lymphoblastic Leukemia-Lymphoma
Intervention: Drug: SGN-CD19A
2 Active, not recruiting A Safety Study of SGN-CD19A for Leukemia and Lymphoma
Conditions: Burkitt Lymphoma;   Precursor B-cell Lymphoblastic Leukemia-Lymphoma
Intervention: Drug: SGN-CD19A
3 Recruiting Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
Conditions: Diffuse, Large B-Cell, Lymphoma;   Follicular Lymphoma, Grade 3b;   Transformed Lymphoma / DLBCL
Interventions: Drug: denintuzumab mafodotin;   Drug: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin;   Drug: vincristine;   Drug: prednisone
4 Recruiting Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma
Conditions: Lymphoma, B-cell;   Lymphoma, Large B-Cell, Diffuse;   Lymphoma, Follicular, Grade 3b;   Follicular Lymphoma, Grade 3b
Interventions: Drug: denintuzumab mafodotin;   Drug: rituximab;   Drug: ifosfamide;   Drug: carboplatin;   Drug: etoposide

Indicates status has not been verified in more than two years